Sartorius Stedim Biotech Shows Steady Growth in 2026

In the first nine months of 2026, Sartorius Stedim Biotech reported a sales revenue of 2,289 million euros, marking a 6.5% growth in constant currencies. Excluding tariff compensations, operational sales soared by 7.8%. This trajectory aligns with the company's expectations, fueled by recurring consumable business and equipment sales.

The firm's underlying EBITDA reached 716 million euros, a margin of 31.3%, with a net profit increase of 26.7% to 277 million euros. These results benefited from positive volumes and strong market fundamentals across all regions, notably a robust 10.6% growth in Asia-Pacific.

Cash flow from operations rose by 11.6% to 498 million euros. The positive earnings and tariff refunds significantly bolstered free cash flow, which surged by 58.5% to 264 million euros.

Despite uncertain market conditions, Sartorius Stedim Biotech maintains its guidance for 2026, anticipating sales revenue growth between 6% and 10% and a slight increase in the EBITDA margin beyond 31%.